Treatment with guselkumab (Tremfya) was effective in resolving enthesitis among patients with psoriatic arthritis (PsA), a post-hoc analysis of two phase III trials found. At week 24, 45% of patients ...

Please provide your email address to receive an email when new articles are posted on . Treatment with guselkumab results in higher enthesitis resolutions rates at week 24, with maintenance of those ...

Please provide your email address to receive an email when new articles are posted on . Children with enthesitis demonstrate worse patient-reported outcomes compared with those without, regardless of ...

Certain new concepts in joint disease are gradually being introduced and treated. One such painful condition is named ‘enthesitis’. Although not exactly a type of ‘arthritis’, enthesitis could be ...

Patients with ankylosing spondylitis taking secukinumab saw improvements in enthesitis, and some achieved complete resolution, suggesting the drug could be a viable option for patients intolerant of ...

Patients with psoriatic arthritis with enthesitis are more likely to have severe disease than patients without enthesitis, and they and their physicians are less likely to be satisfied with their ...

In this cross-sectional study, Poggenborg and colleagues evaluated the ability of an emerging imaging technology, "whole-body" MRI (WBMRI), to detect enthesitis in patients with psoriatic arthritis ...

Around 5% of patients treated with dupilumab (Dupixent) for moderate-to-severe atopic dermatitis experience musculoskeletal (MSK) symptoms, according to the results of a descriptive study. The main ...

Spondyloarthritis (SpA) refers to a spectrum of immune-mediated inflammatory diseases with overlapping features, which differ from other types of inflammatory arthritis in genetic predisposition, ...

The approval was based on data from the 2-year phase 3 JUNIPERA study that evaluated secukinumab in pediatric patients aged 2 to 17 years with a confirmed diagnosis of ERA or JPsA. The Food and Drug ...

Risk factors for the development of inflammatory bowel disease (IBD) among patients with juvenile idiopathic arthritis (JIA) included the subtype of JIA, family history, and medication use, a large ...